Novel Imaging Markers for Rheumatoid Arthritis (NIMRA)
The purpose of this study is to use magnetic resonance imaging (MRI) and high-resolution peripheral quantitative computed tomography (HR-pQCT) techniques to look at the damage and disease activity progression in the hand and wrist joints of patients with rheumatoid arthritis.
The central hypothesis is that ongoing erosions and cartilage loss in rheumatoid arthritis are due to persistent inflammation, which is poorly detected by clinical examination and markers of systemic inflammation.
|Rheumatoid Arthritis||Drug: Cimzia Device: Magnetic Resonance Imaging (MRI) Device: High-resolution peripheral quantitative computed tomography (HR-pQCT)|
|Study Design:||Observational Model: Case-Control
Time Perspective: Cross-Sectional
|Official Title:||Novel Imaging Markers for Rheumatoid Arthritis|
- To better understand how Cimzia and methotrexate affect the damage and disease activity progression in the hand and wrist of patients with rheumatoid arthritis [ Time Frame: up to 2 years ]
Biospecimen Retention: Samples Without DNA
|Study Start Date:||October 2013|
|Estimated Study Completion Date:||May 2018|
|Estimated Primary Completion Date:||January 2018 (Final data collection date for primary outcome measure)|
For the loading phase, it consists of the first 3 doses. During the loading phase, the recommended dose of Cimzia for adults with rheumatoid arthritis is 400mg initially followed by 400mg again at week 2 and week 4. A 400mg dose requires 2 subcutaneous injection of 200mg; the injections should occur at separate sites in the thigh or abdomen.
After the loading dose, will be follow with 200mg every other week. The injection should occur at either the thigh or abdomen.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01773681
|United States, California|
|UCSF - China Basin Imaging Center|
|San Francisco, California, United States, 94107|
|Principal Investigator:||Xiaojuan Li, PhD||University of California, San Francisco|